287 related articles for article (PubMed ID: 31290039)
1. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
Chang JY; Cheon JH
Dig Dis Sci; 2019 Sep; 64(9):2395-2403. PubMed ID: 31290039
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Hindorf U; Lindqvist M; Peterson C; Söderkvist P; Ström M; Hjortswang H; Pousette A; Almer S
Gut; 2006 Oct; 55(10):1423-31. PubMed ID: 16543290
[TBL] [Abstract][Full Text] [Related]
3. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
[TBL] [Abstract][Full Text] [Related]
4. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.
Kakuta Y; Naito T; Onodera M; Kuroha M; Kimura T; Shiga H; Endo K; Negoro K; Kinouchi Y; Shimosegawa T
Pharmacogenomics J; 2016 Jun; 16(3):280-5. PubMed ID: 26076924
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
Relling MV; Schwab M; Whirl-Carrillo M; Suarez-Kurtz G; Pui CH; Stein CM; Moyer AM; Evans WE; Klein TE; Antillon-Klussmann FG; Caudle KE; Kato M; Yeoh AEJ; Schmiegelow K; Yang JJ
Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
[TBL] [Abstract][Full Text] [Related]
6. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Roberts RL; Barclay ML
Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
8. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Relling MV; Gardner EE; Sandborn WJ; Schmiegelow K; Pui CH; Yee SW; Stein CM; Carrillo M; Evans WE; Klein TE;
Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology and pharmacogenetics of thiopurines.
Sahasranaman S; Howard D; Roy S
Eur J Clin Pharmacol; 2008 Aug; 64(8):753-67. PubMed ID: 18506437
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y; Kinouchi Y; Shimosegawa T
J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
13. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
Banerjee R; Ravikanth VV; Pal P; Bale G; Avanthi US; Goren I; Girish BG; Mitnala S; Reddy DN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1683-1694. PubMed ID: 33111378
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
15. [Frequency of serious adverse events of thiopurine treatment in normal thiopurine S-methyltransferase genotype children with inflammatory bowel disease].
Tárnok A
Orv Hetil; 2019 Feb; 160(5):179-185. PubMed ID: 30686035
[TBL] [Abstract][Full Text] [Related]
16. Genotype-based Treatment With Thiopurine Reduces Incidence of Myelosuppression in Patients With Inflammatory Bowel Diseases.
Chang JY; Park SJ; Jung ES; Jung SA; Moon CM; Chun J; Park JJ; Kim ES; Park Y; Kim TI; Kim WH; Cheon JH
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2010-2018.e2. PubMed ID: 31446180
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
Broekman MMTJ; Coenen MJH; Wanten GJ; van Marrewijk CJ; Klungel OH; Verbeek ALM; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; Wong DR; de Jong DJ
Aliment Pharmacol Ther; 2017 Nov; 46(10):953-963. PubMed ID: 28914446
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.
Uchiyama K; Nakamura M; Kubota T; Yamane T; Fujise K; Tajiri H
J Gastroenterol; 2009; 44(3):197-203. PubMed ID: 19214663
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Schwab M; Schäffeler E; Marx C; Fischer C; Lang T; Behrens C; Gregor M; Eichelbaum M; Zanger UM; Kaskas BA
Pharmacogenetics; 2002 Aug; 12(6):429-36. PubMed ID: 12172211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
